Brief Reports
23 July 2025

Getting even: occurrence of histopathological primitive melanoma diagnoses three years after the COVID-19 lockdown

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
38
Views
18
Downloads

Authors

The COVID-19 lockdown in 2020 caused a significant delay in histopathological melanoma diagnoses in Rome, Italy, leading to an increase in Breslow thickness and more aggressive tumor characteristics in the following years. Although there was a partial recovery in the number of diagnoses in 2021 and 2022, melanoma thickness remained higher than pre-pandemic levels. In 2023, our analysis of primary melanoma cases from the Histopathology Registry of Istituto Dermopatico dell’Immacolata (IDI)-IRCCS in Rome showed that Breslow thickness had finally returned to, or even improved beyond, 2019 levels – indicating a resolution of the diagnostic delay. At the same time, the proportion of ulcerated and nodular melanomas declined. These findings underscore the long-term effects of pandemic-related diagnostic disruptions and highlight the importance of maintaining continuous screening programs, even during public health crises. Ongoing public education on melanoma awareness and early detection remains crucial to preventing future delays.

Altmetrics

Downloads

Download data is not yet available.

Citations

1. Ricci F, Fania L, Paradisi A, et al. Delayed melanoma diagnosis in the COVID-19 era: increased breslow thickness in primary melanomas seen after the COVID-19 lockdown. J Eur Acad Dermatol Venereol 2020;34:e778-9. DOI: https://doi.org/10.1111/jdv.16874
2. Ricci F, Di Lella G, Fania L, et al. Primitive melanoma and covid-19: are we still paying the price of the pandemic?. J Eur Acad Dermatol Venereol 2022;36:e260-1. DOI: https://doi.org/10.1111/jdv.17892
3. Ricci F, Abeni D. Heterogeneity of reports about the impact of the COVID-19 pandemic on melanoma diagnosis. Br J Dermatol 2022;187:135-6. DOI: https://doi.org/10.1111/bjd.21598
4. Raza SA, Cannon D, Nuttall G, Ali FR. Exploring the implications of the first COVID-19 lockdown on patients with melanoma: a national survey. Clin Exp Dermatol 2022;47:114-6. DOI: https://doi.org/10.1111/ced.14840
5. Intergruppo Melanoma Italiano. The effect of COVID-19 emergency in the management of melanoma in Italy. Dermatol Reports 2021;13:8972. DOI: https://doi.org/10.4081/dr.2021.8972
6. Pagliarello C, Sicher M, Girardelli CR, Stanganelli I. Prolonged impact of COVID-19 pandemic on delayed melanoma diagnosis: further data based on one-year appraisal from Italy. Dermatol Reports 2022;15:9535. DOI: https://doi.org/10.4081/dr.2022.9535
7. Caini, S., Brusasco, M., Niero, et al. Healthcare and safety of patients with melanoma during the COVID-19 Pandemic in Italy. J Eur Acad Dermatol Venereol 2022;36:e510-2. DOI: https://doi.org/10.1111/jdv.18056

How to Cite



Getting even: occurrence of histopathological primitive melanoma diagnoses three years after the COVID-19 lockdown. (2025). Dermatology Reports. https://doi.org/10.4081/dr.2025.10318